Literature DB >> 25775804

[Stability study in biological samples and metabolites analysis of astragaloside IV in rat intestinal bacteria in vitro].

Gui-Xia Sun, Yuan-Yuan Zhao, Pei-Pei Miao, Xiao-Yan Yang, Qing Miao, Jing Li, Bao-Juan Xue, Jin Su, Yu-Jie Zhang.   

Abstract

To figure out the stability and intestinal bacteria metabolites of rats in vitro of astragaloside IV ( AST), this research was done to explore the stability of AST in the artificial gastric juice. artificial intestinal juice and rat liver homogenate and the metabolism in rat intestinal in vitro. HPLC was used to calculate the remaining rate of AST in biological samples by measuring the content of AST, while metabolites were determined by combining the methods of TLC, HPLC and LC-MS/MS. It turned out that AST was difficult to metabolize in the artificial gastric juice, artificial intestinal juice and rat liver. Also, the metabolic pathway of AST was stepped by deglycosylation. Firstly, AST was converted to its secondary etabolites (6-O-β-D-glucopyranosyl- cycloastragenol, CMG) by removal of xylose moiety at C-3, then transformed into cycloastragenol (CAG) after hydrolytic removal of the glucose moiety at C-6. All the results suggested that the metabolism of AST in vivo occurs mainly in the intestinal by hydrolysis of glycosyl. In conclusion, hydrolysis of intestinal flora is the main reason that AST metabolizes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25775804

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

Review 1.  Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation.

Authors:  Ying Yang; Meng Hong; Wen-Wen Lian; Zhi Chen
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

Review 2.  Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases.

Authors:  Heng-Wen Chen; Jun Li; Yu-Qing Tan
Journal:  Drug Des Devel Ther       Date:  2020-09-15       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.